WO2022260336A2 - 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 - Google Patents
다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2022260336A2 WO2022260336A2 PCT/KR2022/007747 KR2022007747W WO2022260336A2 WO 2022260336 A2 WO2022260336 A2 WO 2022260336A2 KR 2022007747 W KR2022007747 W KR 2022007747W WO 2022260336 A2 WO2022260336 A2 WO 2022260336A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- cancer
- phenyl
- substituted
- mhz
- Prior art date
Links
- 150000003833 nucleoside derivatives Chemical class 0.000 title claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 201000011510 cancer Diseases 0.000 title claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 21
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract description 19
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 6
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 6
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 6
- 201000007270 liver cancer Diseases 0.000 claims abstract description 6
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 6
- -1 tetrahydropyrimidinyl Chemical group 0.000 claims description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 28
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 150000001540 azides Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 2
- 239000004202 carbamide Chemical class 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 claims description 2
- 125000000532 dioxanyl group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000006038 hexenyl group Chemical group 0.000 claims description 2
- 125000005980 hexynyl group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 claims description 2
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 claims description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 claims description 2
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 claims description 2
- 125000005981 pentynyl group Chemical group 0.000 claims description 2
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001166 thiolanyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract description 9
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 abstract description 8
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 abstract description 7
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 abstract description 7
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract description 7
- 102000001253 Protein Kinase Human genes 0.000 abstract description 5
- 108060006633 protein kinase Proteins 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 2
- 102100037402 Casein kinase I isoform delta Human genes 0.000 abstract 1
- 101001026336 Homo sapiens Casein kinase I isoform delta Proteins 0.000 abstract 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 abstract 1
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 abstract 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 103
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- 230000015572 biosynthetic process Effects 0.000 description 55
- 238000003786 synthesis reaction Methods 0.000 description 55
- 238000002360 preparation method Methods 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 52
- 238000004896 high resolution mass spectrometry Methods 0.000 description 41
- 238000005481 NMR spectroscopy Methods 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 30
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 27
- 238000001308 synthesis method Methods 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 22
- 238000010898 silica gel chromatography Methods 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 19
- 239000010410 layer Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000003960 organic solvent Substances 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 108010040648 Dyrk kinase Proteins 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- YRTFLDFDKPFNCJ-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCN1CCCC1 YRTFLDFDKPFNCJ-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 6
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- 229940126657 Compound 17 Drugs 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- DYMCRSCIKQMSRP-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide Chemical compound N1C=NC=C2C(C(=O)N)=CN=C21 DYMCRSCIKQMSRP-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 4
- 229940125833 compound 23 Drugs 0.000 description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 3
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 3
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 3
- HCLQARMRCPEALF-DNQXCXABSA-N 3-[[(2r)-2-[(1r)-2-[[1-(1-benzothiophen-2-yl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]pyrrolidin-1-yl]methyl]benzonitrile Chemical compound C([C@@H]1[C@H](O)CNC(C)(CC=2SC3=CC=CC=C3C=2)C)CCN1CC1=CC=CC(C#N)=C1 HCLQARMRCPEALF-DNQXCXABSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 2
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 2
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 2
- YCGQPIRMLGEWMW-UHFFFAOYSA-N 1-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]-3-[4-[(dimethylamino)methyl]-2,6-di(propan-2-yl)phenyl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN(C)C)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 YCGQPIRMLGEWMW-UHFFFAOYSA-N 0.000 description 2
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 2
- OXTVBHDILDPYAS-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 OXTVBHDILDPYAS-UHFFFAOYSA-N 0.000 description 2
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 2
- FJMQJSUOOGOWBD-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one Chemical compound O=C1N(CC(F)(F)C)CCOC=2C1=NN(C=1C(=CC=CC=1)Cl)C=2C1=CC=C(Cl)C=C1 FJMQJSUOOGOWBD-UHFFFAOYSA-N 0.000 description 2
- CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 2
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- OHVIRCSJFFPEGC-XMMPIXPASA-N N-[3-[[4-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl]phenyl]methoxy]phenyl]benzamide Chemical compound OC[C@H]1CCCN1Cc1ccc(COc2cccc(NC(=O)c3ccccc3)c2)cc1 OHVIRCSJFFPEGC-XMMPIXPASA-N 0.000 description 2
- RTHSEYQQWBBPHL-UHFFFAOYSA-N N1=CC(=CC=C1)C1=C2C=CC=NC2=C(C=C1)NS(=O)(=O)C1=CC(=CC=C1)C(F)(F)F Chemical compound N1=CC(=CC=C1)C1=C2C=CC=NC2=C(C=C1)NS(=O)(=O)C1=CC(=CC=C1)C(F)(F)F RTHSEYQQWBBPHL-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- DDIZAANNODHTRB-UHFFFAOYSA-N methyl p-anisate Chemical compound COC(=O)C1=CC=C(OC)C=C1 DDIZAANNODHTRB-UHFFFAOYSA-N 0.000 description 2
- LVBWRNKEBGYENR-UHFFFAOYSA-N n-cyclopropyl-4-[8-(oxan-4-ylmethylamino)-6-[(1,1,1-trifluoro-2-methylpropan-2-yl)amino]imidazo[1,2-b]pyridazin-3-yl]benzamide Chemical compound C12=NC=C(C=3C=CC(=CC=3)C(=O)NC3CC3)N2N=C(NC(C)(C)C(F)(F)F)C=C1NCC1CCOCC1 LVBWRNKEBGYENR-UHFFFAOYSA-N 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- VXZBYIWNGKSFOJ-UHFFFAOYSA-N 2-[4-[5-(2,3-dihydro-1H-inden-2-ylamino)pyrazin-2-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC=1N=CC(=NC=1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 VXZBYIWNGKSFOJ-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- APLNAFMUEHKRLM-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)N=CN2 APLNAFMUEHKRLM-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- FRNQQVVVYMQEIV-UHFFFAOYSA-N 2-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound IC=1N=C(C2=C(N=1)NC=C2)N FRNQQVVVYMQEIV-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 1
- MVXAKOGJWVQPKC-UHFFFAOYSA-N 5-(3-ethynyl-5-fluorophenyl)-2-pyridin-2-yl-4,6,7,8-tetrahydro-[1,3]oxazolo[4,5-c]azepine Chemical compound FC1=CC(C#C)=CC(N2CC=3N=C(OC=3CCC2)C=2N=CC=CC=2)=C1 MVXAKOGJWVQPKC-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- GDYUNCUMRKXRHY-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound N1C=NC=C2C(C#N)=CN=C21 GDYUNCUMRKXRHY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- KNAMBROHFPWGMW-JHZZHVAFSA-N CC(C)(C)C#CC1=CN([C@@H]2S[C@H](CO[Si](C(C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)[C@H]3OC(C)(C)O[C@@H]23)C2=C1C(N)=NC=N2 Chemical compound CC(C)(C)C#CC1=CN([C@@H]2S[C@H](CO[Si](C(C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)[C@H]3OC(C)(C)O[C@@H]23)C2=C1C(N)=NC=N2 KNAMBROHFPWGMW-JHZZHVAFSA-N 0.000 description 1
- CZZKGLTUISCHJT-QWOIFIOOSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C#CC)C2=C1C(N)=NC=N2 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C#CC)C2=C1C(N)=NC=N2 CZZKGLTUISCHJT-QWOIFIOOSA-N 0.000 description 1
- PDLIJEBDZVVHAH-JHZZHVAFSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C#CC2CC2)C2=C1C(N)=NC=N2 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C#CC2CC2)C2=C1C(N)=NC=N2 PDLIJEBDZVVHAH-JHZZHVAFSA-N 0.000 description 1
- DXUFDCRLTLLAKW-JHZZHVAFSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C#C[Si](C)(C)C)C2=C1C(N)=NC=N2 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C#C[Si](C)(C)C)C2=C1C(N)=NC=N2 DXUFDCRLTLLAKW-JHZZHVAFSA-N 0.000 description 1
- LTRMNLRRTWLWRT-UTBAFCPYSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C2=CC=CC=C2)C2=C1C(N)=NC=N2 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C2=CC=CC=C2)C2=C1C(N)=NC=N2 LTRMNLRRTWLWRT-UTBAFCPYSA-N 0.000 description 1
- ZODBOBSUIVCFMJ-DWCTZGTLSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C2=CC=CO2)C2=C1C(N)=NC=N2 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C2=CC=CO2)C2=C1C(N)=NC=N2 ZODBOBSUIVCFMJ-DWCTZGTLSA-N 0.000 description 1
- XZICWBIHFIISPV-BQOYKFDPSA-N CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C=C)C2=C1C(N)=NC=N2 Chemical compound CC(C)(C)[Si](C1=CC=CC=C1)(C1=CC=CC=C1)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)S[C@H]1N(C=C1C=C)C2=C1C(N)=NC=N2 XZICWBIHFIISPV-BQOYKFDPSA-N 0.000 description 1
- FQFLFBUPDCCVFZ-PBXRRBTRSA-N CC1(C)O[C@H]2[C@@H](O)SC[C@H]2O1 Chemical compound CC1(C)O[C@H]2[C@@H](O)SC[C@H]2O1 FQFLFBUPDCCVFZ-PBXRRBTRSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000008122 Casein Kinase I Human genes 0.000 description 1
- 108010049812 Casein Kinase I Proteins 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 241000021559 Dicerandra Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- VCOGUPJMAZQDGK-SDBHATRESA-N NC1=NC=NC2=C1C(C1=CC=CO1)=CN2[C@@H]([C@@H]1O)S[C@H](CO)[C@H]1O Chemical compound NC1=NC=NC2=C1C(C1=CC=CO1)=CN2[C@@H]([C@@H]1O)S[C@H](CO)[C@H]1O VCOGUPJMAZQDGK-SDBHATRESA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- BCTJSQNYHKAOSK-GCJDJSOWSA-N [(3aR,6aS)-2,2-dimethyl-3a,4,6,6a-tetrahydrothieno[3,4-d][1,3]dioxol-4-yl] acetate Chemical compound O1C(C)(C)O[C@H]2C(OC(=O)C)SC[C@H]21 BCTJSQNYHKAOSK-GCJDJSOWSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XJMULMWDHLJUKP-UHFFFAOYSA-N methyl 2,6-dimethylbenzoate Chemical compound COC(=O)C1=C(C)C=CC=C1C XJMULMWDHLJUKP-UHFFFAOYSA-N 0.000 description 1
- LXNFVVDCCWUUKC-UHFFFAOYSA-N methyl 4-chlorobenzoate Chemical compound COC(=O)C1=CC=C(Cl)C=C1 LXNFVVDCCWUUKC-UHFFFAOYSA-N 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WVKNBCACIPKHEW-UHFFFAOYSA-N n,n-diethylethanamine;n,n-dimethylformamide Chemical compound CN(C)C=O.CCN(CC)CC WVKNBCACIPKHEW-UHFFFAOYSA-N 0.000 description 1
- HWWVAHCWJLGKLW-UHFFFAOYSA-N n,n-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WONPWMKTZAPWSP-UHFFFAOYSA-N thiolane-3,4-diol Chemical compound OC1CSCC1O WONPWMKTZAPWSP-UHFFFAOYSA-N 0.000 description 1
- MPKQTNAUFAZSIJ-UHFFFAOYSA-N thiophene-3,4-diol Chemical compound OC1=CSC=C1O MPKQTNAUFAZSIJ-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- SIOVKLKJSOKLIF-HJWRWDBZSA-N trimethylsilyl (1z)-n-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N\[Si](C)(C)C SIOVKLKJSOKLIF-HJWRWDBZSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010064884 trkA Receptor Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Definitions
- the present invention relates to a nucleoside derivative that can be used for preventing or treating cancer by inhibiting kinase and a pharmaceutical composition containing the same.
- Protein kinases play an important role in cellular function by mediating the phosphorylation of proteins. Since they transfer the terminal phosphate group of adenosine triphosphate (ATP) to a protein substrate, reactions such as signal transduction, gene regulation, and metabolism occur, dysregulation of kinases can be associated with various diseases, including cancer. Therefore, if a nucleoside derivative is developed by targeting a kinase, it can be used for cancer treatment.
- ATP adenosine triphosphate
- Multi-target inhibitors that target more than one target can overcome the effects of single-target inhibitors by blocking the proliferation of cancer cells and, second, by blocking the microenvironment that supports tumorigenesis.
- the nitrogenous base of ATP interacts with the hinge region and the ribose ring with the polar residues of the sugar pocket through hydrogen bonding, whereas known kinase inhibitors do not bind to the sugar pocket and occupy either the hinge region or the hydrophobic region. Therefore, the present inventors recognized that the hydrophobic pocket to which ATP does not bind is an important site for the development of inhibitors in the design of selective kinase inhibitors.
- a nitrogen base forms a hydrogen bond with the hinge region and phosphorylates a nucleoside occupying a hydrophobic pocket by modifying a hydrophobic residue (R 1 in Formula 1 below) and another hydrophobic residue (R 2 in Formula 1 below).
- Enzyme inhibitors were designed. It was also found that, like the ribose ring of ATP, the polar hydroxyl group of the sugar forms a hydrogen bond with the sugar site, making the molecule fit together and increasing the binding force.
- the kinase inhibitory activity of the synthesized compounds was evaluated based on the fact that this part forms an important bond to the triphosphate binding site of the kinase domain.
- the present invention was completed by finding effective selective inhibitors for NTRK1, DYRK1A, DYRK1B, FLT3, and CSNK1D, which are phosphorylation enzymes associated with overexpression in cancer cells, and confirming that they exhibit excellent anticancer activity.
- an object to be solved by the present invention is to provide a nucleoside derivative that can be used for preventing or treating cancer by selectively inhibiting a specific kinase and a pharmaceutical composition containing the same.
- a nucleoside derivative according to an embodiment of the present invention for solving the above problems is represented by Formula 1 below.
- X is oxygen (O) or sulfur (S);
- R is hydrogen (H); A substituted or unsubstituted C 1 to C 10 alkyl; or a substituted or unsubstituted C 6 to C 20 aryl or alkylaryl;
- R 1 is a substituted or unsubstituted C 2 to C 10 heteroaryl; Substituted or unsubstituted C 2 to C 8 alkenyl; A substituted or unsubstituted C 6 to C 20 aryl; A substituted or unsubstituted C 2 to C 8 alkynyl; cyano; amide; or carboxyl,
- R 2 is halogen; A substituted or unsubstituted amine; or a substituted or unsubstituted C 6 to C 20 aryl or alkylaryl;
- R, R 1 , R 2 and Y When R, R 1 , R 2 and Y are substituted, they may be substituted with one or more of C 1 to C 6 alkyl, C 2 to C 10 heteroaryl, and sulfonamide.
- the heteroaryl is furanyl, thiophenyl, pyrrolyl, pyranyl, pyrazolyl, pyridinyl, triazolyl, imidazolyl (imidazolyl), thiazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, quinolinyl or purinyl can
- the heterocycloalkyl is tetrahydrofuranyl, thiolanyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, dioxanyl, molar It may be morpholino or tetrahydropyrimidinyl.
- the aryl may be phenyl, naphthalenyl, anthracenyl, or phenanthrenyl, and the alkylaryl may be benzyl.
- the alkynyl is ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl ) or decynyl.
- the alkenyl is ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl ) or decenyl.
- the alkyl may be methyl, ethyl, propyl, butyl or pentyl.
- X may be sulfur
- R may be hydrogen
- R 1 is furanyl, thiophenyl, vinyl, phenyl, thiomorpholino phenyl , Thiomorpholinodioxide phenyl, sulfonamide phenyl, ethyl sulfonamide phenyl, ethynyl, propynyl, butynyl, dimethylbutynyl, cyclopropylethynyl ( cyclopropylethynyl), cyano, amide, or carboxy
- R 2 can be chlorine (Cl) or amine (-NH 2 )
- Y is hydrogen, -CH 2 OH, - CH 2 OCOAr, -CH 2 N 3 , -CH 2 NH 2 , -CH 2 NHCOAr, -CH 2 NHCONH 2 , -CH 2 N-alkyl, -CH 2 N-cycloalkyl, -CH
- 'Ar' is aryl and may be phenyl, chlorophenyl, methoxyphenyl, dimethylphenyl or nicotinyl
- 'alkyl' is methyl, ethyl, propyl, butyl Or it may be pentyl
- the 'cycloalkyl' may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- nucleoside derivatives according to an embodiment of the present invention are represented by the following formulas 1a - 1b, 2a - 2d, 3, 4a - 4d, 5, 6, 7a - 7h, 8a - 8e, 9a - 9c, 10a - 10c, 11ai - 11aiii, 11b, 12a - 12b, 13a - 13g and can be expressed as one of 14.
- the nucleoside derivative of the present invention may be provided in the form of a pharmaceutically acceptable salt.
- a pharmaceutically acceptable salt As the salt, acid addition salts formed by various pharmaceutically acceptable organic or inorganic acids are useful.
- nucleoside derivatives of the present invention may be provided in the form of all salts, hydrates, and solvates that can be prepared by conventional methods.
- the nucleoside derivatives of the present invention have inhibitory activity against kinases such as NTRK1, CSNK1D, DYRK1A, DYRK1B and FLT3 (see Experimental Example 1), and thus directly or indirectly interact with kinases. Since it exhibits inhibitory activity against various related cancer cells (see Experimental Example 2), lung cancer, colon cancer, breast cancer, liver cancer, stomach cancer and prostate cancer (Prostate cancer) can be included in a pharmaceutical composition that can prevent or treat various cancers.
- the pharmaceutical composition for preventing or treating cancer of the present invention may include the nucleoside derivative or a pharmaceutically acceptable salt thereof, and the cancer is composed of lung cancer, colon cancer, breast cancer, liver cancer, stomach cancer and prostate cancer. It may be one or more selected from the group, and the nucleoside derivative or a pharmaceutically acceptable salt thereof may have a kinase inhibitory activity.
- the pharmaceutical composition may be administered systemically or locally, and may be formulated using excipients (or diluents) such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. that can be generally used for administration. .
- the preferred dosage of the pharmaceutical composition varies depending on a number of factors such as the condition and weight of the patient, the severity of the disease, the drug type, the route and duration of administration, but can be appropriately selected by those skilled in the art. Also, the route of administration may vary depending on the patient's condition and its severity.
- Nucleoside derivatives or pharmaceutically acceptable salts thereof according to embodiments of the present invention have inhibitory activity against kinases such as NTRK1, CSNK1D, DYRK1A, DYRK1B, and FLT3, and accordingly, kinases and Since it exhibits inhibitory activity against various cancer cells that are directly or indirectly involved, lung cancer, colon cancer, breast cancer, liver cancer, stomach cancer and prostate cancer ) can be used to prevent or treat various cancers, such as
- Terminology used herein is for describing the embodiments and is not intended to limit the present invention.
- 'and/or' includes each and every combination of one or more of the recited items.
- singular forms also include plural forms unless otherwise specified in the text.
- the terms 'comprises' and/or 'comprising' used in the specification do not exclude the presence or addition of one or more other elements other than the mentioned elements.
- Numerical ranges expressed using '-' or 'to' indicate numerical ranges including the values listed before and after them as lower and upper limits, respectively, unless otherwise specified.
- 'About' or 'approximately' means a value or range of values within 20% of the value or range of values set forth thereafter.
- 'prevention means suppressing the occurrence of a symptom or disease in a subject who does not yet have the symptom or disease, but is susceptible to such a symptom or disease.
- 'treatment' refers to (a) inhibition of the development (exacerbation) of a symptom or disease, (b) alleviation or improvement of a symptom or disease, or (c) elimination of a symptom or disease in a subject.
- 'subject' means an animal, especially a mammal, including humans, having a symptom or disease that can be 'prevented' or 'treated' by administering the composition of the present invention.
- a compound of 'substituted C n to C n + m ' refers to a case in which the number of all carbons of the compound including the substituted part is n to n + m, as well as the number of carbon atoms of the compound excluding the substituted part. The number also includes n to n+m.
- Compound 12a was synthesized from Compound 33 in 20% yield (2 steps) through the known synthesis method (H).
- Compound 12b was synthesized from Compound 34 in a yield of 43% through the known synthesis method (H).
- Triethylamine (21.5 mL, 154.62 mmol) was added to a solution of compound 37 (5.45 g, 30.92 mmol) dissolved in dichloromethane (54 mL) while stirring, and then acetic anhydride (5.8 mL, 61.85 mmol) was added to 0. It was added dropwise at °C.
- the reaction solution was stirred at room temperature for 6 hours, and after completion of the reaction with saturated sodium bicarbonate solution, it was extracted three times with ethyl acetate. The collected organic solvent layers were dried, filtered under reduced pressure, and concentrated under reduced pressure. This compound was so pure that it could be used directly in the next reaction.
- Compound 41a was synthesized from compound 40 through the known synthesis method (D).
- Compound 41ai was synthesized from compound 41a through the known synthesis method (E).
- Compound 41b-c was synthesized from compound 40 through the known synthesis method (A).
- Compound 41d-e was synthesized from compound 40 through the known synthesis method (C).
- Compound 41f-g was synthesized from compound 40 through the known synthesis method (A).
- Compounds 41a-41g were used in the next reaction without purification.
- reaction mixture After neutralization with a saturated aqueous solution of sodium hydrogen carbonate, the reaction mixture was partitioned between ethyl acetate and water and extracted three times with ethyl acetate. The organic solvent layer was dried over anhydrous MgSO 4 , filtered and evaporated. The residue was purified by silica gel column chromatography to obtain compound 43 (780.9 mg, 41%) as a yellow syrup.
- reaction mixture was partitioned between ethyl acetate and water, extracted three times with ethyl acetate, dried over anhydrous MgSO 4 , filtered and evaporated. The residue was purified by silica gel column chromatography to obtain compound 44 (60.2 mg, 53%) as a yellow syrup.
- NTRK1 Neurotrophic tyrosine kinase receptor type 1 or Tropomyosin receptor kinase A
- CSNK1D Cyasein kinase 1 isoform delta
- DYRK1A Dual specificity tyrosine-phosphorylation-regulated kinase 1A
- DYRK1B Dual specificity tyrosine-phosphorylation-regulated kinase 1B
- FLT3 Receptor-type tyrosine-protein kinase or fms like tyrosine Kinase 3 or cluster of differentiation antigen 135 (CD135) or fetal liver kinase-2 (Flk2)
- the inhibition measurement method was as follows. Most of the phosphorylation enzymes were produced by culturing BL21 E. coli with kinase-tagged phages at 32° C. until they were lysed, followed by centrifugation and filtration. It was also produced using HEK-293 cells. DNA was then tagged for qPCR. After stirring the biotin-tagged substrate on the streptavidin-coated beads for 30 minutes to form an affinity resin, the non-specifically bound substrate was mixed with a buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) was washed with a buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) was washed with
- kinase, substrate, affinity resin, and test substances dissolved in dimethyl sulfoxide were mixed in a buffer (20% SeaBlock, 0.17x PBS, 0.05% Tween 20, 6 mM DTT) and stirred at room temperature for 1 hour. . After washing the affinity matrix with buffer (1x PBS, 0.05% Tween 20), it was suspended in elution buffer (1x PBS, 0.05% Tween 20, 0.5 ⁇ M non-biotinylated affinity ligand) and stirred. Phosphorase concentration was quantified by qPCR.
- Table 9 shows the results of treating each kinase with 1 ⁇ M of Compounds 1a to 14, (-) has no effect; (+) indicates weak inhibitory activity; (++) indicates moderate inhibitory activity; (+++) strong inhibitory activity; ND means not determined.
- nucleoside derivatives of the present invention have generally excellent inhibitory activity against kinases such as NTRK1, CSNK1D, DYRK1A, DYRK1B and FLT3.
- A549 (Lung cancer cells), HCT116 (Colon cancer cells), MDA-MB-231 (Breast cancer cells), SK-Hep- 1 (Liver cancer cells), SNU638 (Stomach cancer cells), and PC-3 (Prostate cancer cells) were measured for IC 50 of cancer cells.
- the test method was as follows. The cells were allowed to stand for one day and set as a day 0 control group. In addition, after adding the test substance to the cells, they were allowed to stand for 3 days. Then, they were stained with 1% acetic acid and 0.4% sulforhodamine B. The stained cells were dried and dissolved in 10 mM Tris (pH 10.0). Absorbance was measured at 515 nm, and the degree of cell division was obtained by the following formula.
- Cell division (%) (average absorbance test substance - average absorbance on day 0 ) / (average absorbance control - average absorbance on day 0 ) x 100, and TableCurve 2D v5.01 (Systat Software Inc., San Jose, CA, USA) ) was calculated through nonlinear regression analysis.
- the nucleoside derivatives of the present invention showed generally low IC 50 values against cancer cells such as A549, HCT116, MDA-MB-231, SK-Hep-1, SNU638 and PC-3. Therefore, it can be seen that it can be used as a kinase inhibitor that can be expected to have an anticancer effect.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Compound |
NMR Solvent/Frequency | 1H NMR data (Chemical shift, δ ppm) | |||||||
1' | 2' | 3' | 4' | 5' | 2 | 7 (R1 group) | 8 | ||
1a (R1 = 2-furanyl) |
DMSO-d
6/ 500 MHz |
6.17 (d, J = 7.0 Hz, 1H) | 4.48-4.45 (m, 1H) | 4.19-4.18 (m, 1H) | 3.29-3.28 (m, 1H) | 3.78-3.75 (m, 1H), 3.63-3.58 (m, 1H) | 8.13 (s, 1H) | 7.95 (s, 1H), 6.72 (d, J = 3.0 Hz, 1H), 6.62-6.61 (m, 1H) | 7.78 (s, 1H) |
1b(R1 = 2-thiofuranyl) | CD3OD/500 MHz | 6.22 (d, J = 5.9 Hz, 1H) | 4.52 (q, J = 5.7, 3.7 Hz, 1H) | 4.29 (t, J = 3.8 Hz, 1H) | 3.48 (q, J = 9.4, 4.8 Hz, 1H) | 3.88-3.80 (m, 2H) | 8.13 (s, 1H) | 7.42 (d, J = 5.0 Hz, 1H), 7.14-7.11 (m, 2H) | 7.66 (s, 1H) |
2a(R1 = vinyl) | DMSO-d 6/500 MHz | 6.12 (d, J = 7.0 Hz, 1H) | 4.46-4.41 (m, 1H) | 4.18-4.14 (m, 1H) | 3.24 (m, 1H) | 3.77-3.72 (m, 1H), 3.61-3.55 (m, 1H) | 8.04 (s, 1H) | 7.10 (dd, J = 17.2, 10.9 Hz, 1H), 5.59 (d, J = 17.1 Hz, 1H), 5.11 (d, J = 11.0 Hz, 1H), | 7.77 (s, 1H) 3.27- |
2b (R1 = phenyl) | DMSO-d 6/500 MHz | 6.18 (d, J = 6.9 Hz, 1H) | 4.51-4.47 (m, 1H) | 4.19-4.16 (m, 1H) | 3.29-3.25 (m, 1H) | 3.77-3.71 (m, 1H), 3.61-3.56 (m, 1H) | 8.14 (s, 1H) | 7.50-7.46 (m, 4H), 7.38-7.34 (m, 1H) | 7.66 (s, 1H) |
2c(R1 =) | DMSO-d
6/500 MHz |
6.18 (d, J = 6.9 Hz, 1H) | 4.49-4.47 (m, 1H) | 4.18-4.17 (m, 1H) | 3.29-3.27 (m, 1H) | 3.75-3.72 (m, 1H), 3.60-3.57 (m, 1H) | 8.13 (s, 1H) | 7.35 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H), 3.84 (s, 4H), 3.14 (s, 4H) | 7.54 (s, 1H) |
2d(R1 =) | DMSO-d 6/500 MHz) | 6.18 (d, J = 6.9 Hz, 1H) | 4.49-4.46 (m, 1H) | 4.19-4.17 (m, 1H) | 3.29-3.27 (m, 1H) | 3.76-3.72 (m, 1H), 3.61-3.57 (m, 1H) | 8.14 (s, 1H) | 9.87 (s, 1H), 7.42 (merged dd, J 1 = J 2 = 8.2 Hz, 2H), 7.31 (merged dd, J 1 = J 2 = 8.1 Hz, 2H), 3.13 (q, J = 14.4, 7.1 Hz, 2H), 1.22 (t, J = 7.2 Hz, 3H) | 7.60 (s, 1H) |
3(R1 = acetylene) | DMSO-d 6/500 MHz | 6.06 (d, J = 6.9 Hz, 1H) | 4.45-4.42 (m, 1H) | 4.16-4.14 (m, 1H) | 3.28-3.25 (m, 1H) | 3.76-3.71 (m, 1H), 3.61-3.57 (m, 1H) | 8.12 (s, 1H) | 4.28 (s, 1H) | 7.93 (s, 1H) |
4a(R1 = prop-1-yn-1-yl) | DMSO-d 6/500 MHz | 6.05 (d, J = 6.7 Hz, 1H) | 4.42-4.39 (m, 1H) | 4.16-4.13 (m, 1H) | 3.27-3.24 (m, 1H) | 3.75-3.70 (m, 1H), 3.61-3.56 (m, 1H) | 8.10 (s, 1H) | 2.08 (s, 3H) | 7.75 (s, 1H) |
4b(R1 = but-1-yn-1-yl) | DMSO-d
6/500 MHz) |
6.06 (d, J = 6.8 Hz, 1H) | 4.43-4.40 (m, 1H) | 4.16-4.13 (m, 1H) | 3.27-3.24 (m, 1H) | 3.75-3.70 (m, 1H), 3.60-3.56 (m, 1H) | 8.10 (s, 1H) | 2.47 (q, J = 14.9, 7.4 Hz, 2H), 1.17 (t, J = 7.4 Hz, 3H) | 7.76 (s, 1H) |
4c(R1 = 3,3-dimethylbut-1-yn-1-yl) | DMSO-d 6/500 MHz | 6.06 (d, J = 7.0 Hz, 1H) | 4.45-4.41 (m, 1H) | 4.16-4.13 (m, 1H) | 3.27-3.24 (m, 1H) | 3.76-3.71 (m, 1H), 3.61-3.55 (m, 1H) | 8.11 (s, 1H) | 1.31 (s, 9H) | 7.76 (s, 1H) |
4d(R1 = cyclopropylethynyl) | CD3OD/500 MHz |
6.12 (d, J = 5.9 Hz, 1H) | 4.44 (dd, J = 5.8, 3.7 Hz, 1H) | 4.25-4.23 (m, 1H) | 3.48-3.44 (m, 1H) | 3.88-3.79 (m, 2H) | 8.10 (s, 1H) | 1.56-1.50 (m, 1H), 0.93-0.88 (m, 2H), 0.78-0.74 (m, 2H) | 7.68 (s, 1H) |
5(R1 = CN) |
CD3OD/400 MHz | 6.14 (d, J = 5.6 Hz, 1H) |
4.47 (dd, J 1 = 4.0 Hz, J 2 = 5.6 Hz, 1H) | 4.23 (superimposed dd, J 1 = J 2 = 4.0 Hz, 1H) | 3.51-3.46 (m, 1H) | 3.87-3.83 (m, 2H) | 8.40 (s, 1H) | __ | 8.20 (s, 1H) |
6(R1 = CONH2) |
CD3OD/400 MHz | 6.22 (d, J = 6.0 Hz, 1H) | 4.49 (dd, J 1 = 4.0 Hz, J 2 = 6.0 Hz, 1H) | 4.29 (superimposed dd, J 1 = J 2 = 4.0 Hz, 1H) | 3.58-3.53 (m, 1H) | 3.95-3.89 (m, 2H) | 8.35 (s, 1H) | __ | 8.13 (s, 1H) |
Compound | HRMS, m/z [M + H]+ | Molecular formula |
1a (R1 = 2-furanyl) |
349.0974 | C15H17N4O4S |
1b (R1 = 2-thiofuranyl) | 365.0749 | C15H17N4O3S2 |
2a(R1 = vinyl) | 309.1018 | C13H17N4O3S |
2b (R1 = phenyl) | 359.1177 | C17H19N4O3S |
2c(R1 = ) | 492.1388 | C21H26N5O5S2 |
2d(R1 = ) | 466.1225 | C19H24N5O5S2 |
3 (R1 = acetylene) | 307.0863 | C13H15N4O3S |
4a(R1 = prop-1-yn-1-yl) | 321.1013 | C14H17N4O3S |
4b(R1 = but-1-yn-1-yl) | 335.1157 | C15H19N4O3S |
4c(R1 = 3,3-dimethylbut-1-yn-1-yl) | 363.1475 | C17H23N4O3S |
4d(R1 = cyclopropylethynyl) | 347.1159 | C16H19N4O3S |
5(R1 = CN) | 307.0808 | C12H14N5O3S |
6(R1 = CONH2) | 326.0921 | C12H16N5O4S |
Compound |
NMR Solvent/Frequency | 1H NMR data (Chemical shift, δ ppm) | ||||||||
1' | 2' | 3' | 4' | 5' | Y group | 2 | 7 (R1 group) | 8 | ||
7a (X = O, R1 = 2-furanyl, Y = phenyl) |
DMSO-d 6/400 MHz | 6.23 (d, J = 6.4 Hz, 1H) | 4.62-4.58 (m, 1H) | 4.34-4.30 (m, 1H) |
3.66-3.61(m, 1H) | 4.75 (dd, 10.9, 6.8 Hz, 1H), 4.51 (dd, J = 11.0, 6.8 Hz, 1H) | 7.99 (merged dd, J 1 = J 2 = 7.3 Hz, 2H), 7.68 (merged dd, J 1 = J 2 = 7.3 Hz, 1H), 7.53 (merged dd, J 1 = J 2 = 7.7 Hz, 2H) | 8.14 (s, 1H) | 7.79-7.77 (m, 1H), 6.63-6.59 (m, 2H) | 7.91 (s, 1H) |
7b(X = O, R1 = ethynyl, Y = phenyl) |
CD3OD/400 MHz | 6.16 (d, J = 5.5 Hz, 1H) | 4.50-4.46 (m, 1H) | 4.35-4.31 (m, 1H) | 3.79-3.74 (m, 1H) | 4.80-4.72 (m, 1H), 4.59-4.51 (m, 1H) | 8.09-8.03 (m, 2H), 7.63-7.60 (m, 1H), 7.52-7.49 (m, 2H) | 8.10 (s, 1H) | 3.70 (s, 1H) | 7.70 (s, 1H) |
7c(X = O, R1 = ethynyl, Y = p-chlorophenyl) | DMSO-d 6/400 MHz | 6.08 (d, J = 6.1 Hz, 1H) | 4.53-4.51 (m, 1H) | 4.24-4.20 (m, 1H) | 3.60-3.56 (m, 1H) | 4.71-4.68 (m, 1H), 4.50-4.42 (m, 1H) | 7.96-7.94 (m, 2H), 7.60-7.58 (m, 2H) | 8.09 (s, 1H) | 4.25 (s, 1H) | 7.87 (s, 1H) |
7d(X = O, R1 = ethynyl, Y = p-methoxyphenyl) | CD3OD/400 MHz | 6.14 (d, J = 5.6 Hz, 1H) | 4.50-4.46 (m, 1H) | 4.34-4.31 (m, 1H) | 3.76-3.72 (m, 1H) | 4.76-4.71 (m, 1H), 4.54-4.50 (m, 1H) | 8.02-7.98 (m, 2H), 7.03-6.99 (m, 2H), 3.85 (s, 3H) | 8.10 (s, 1H) | 3.70 (s, 1H) | 7.67 (s, 1H) |
7e(X = O, R1 = ethynyl, Y 2,6-dimethylphenyl) | CD3OD/400 MHz | 6.15 (d, J = 4.8 Hz, 1H) | 4.44-4.41 (m, 1H) | 4.29-4.25 (m, 1H) | 3.77-3.72 (m, 1H) | 4.75-4.70 (m, 1H), 4.61-4.56 (m, 1H) | 7.23-7.18 (m, 1H), 7.08-7.05 (m, 2H), 2.31 (s, 6H) | 8.10 (s, 1H) | 3.67 (s, 1H) | 7.56 (s, 1H) |
7f(X = O, R1 = ethynyl, Y = isonicotinyl) | DMSO-d 6/400 MHz | 6.11 (d, J = 6.1 Hz, 1H) | 4.55-4.53 (m, 1H) | 4.30-4.28 (m, 1H) | 3.65-3.61 (m, 1H) | 4.79-4.75 (m, 1H), 4.56-4.54 (m, 1H) | 8.84-8.82 (m, 2H), 7.86-7.85 (m, 2H) | 8.13 (s, 1H) | 4.29 (s, 1H) | 7.92 (s, 1H) |
7g(X = O, R1 = CN, Y = phenyl) | CD3OD/400 MHz | 6.18 (d, J = 5.4 Hz, 1H) | 4.55-4.42 (m, 1H) | 4.38-4.35 (m, 1H) | 3.76-3.70 (m, 1H) | 4.92-4.79 (m, 1H), 4.60-4.56 (m, 1H) | 8.0-7.69 (m, 2H), 7.66-7.58 (m, 1H), 7.54-7.47 (m, 2H) | 8.16 (s, 1H) | __ | 7.90 (s, 1H) |
7h(X = O, R1 = CONH2, Y = phenyl) | CD3OD/400 MHz | 6.17 (d, J = 5.3 Hz, 1H) | 4.53-4.39 (m, 1H) | 4.36-4.32 (m, 1H) | 3.79-3.72 (m, 1H) | 4.90-4.78 (m, 1H), 4.62-4.55 (m, 1H) | 8.05-7.73 (m, 2H), 7.67-7.56 (m, 1H), 7.55-7.45 (m, 2H) | 8.15 (s, 1H) | __ | 7.89 (s, 1H) |
8a(X = NH, R1 = 2-furanyl, Y = phenyl) |
DMSO-d 6/400 MHz | 6.17 (d, J = 7.2 Hz, 1H) | 4.56-4.50 (m, 1H) | 4.20-4.16 (m, 1H) | 3.44-3.38 (m, 1H) | 3.78-3.70 (m, 1H), 3.55-3.48 (m, 1H) | 7.85-7.82 (m, 2H), 7.52-7.48 (m, 1H), 7.46-7.40 (m, 2H) | 8.09 (s, 1H) | 7.75-7.74 (m, 1H), 6.66-6.64 (m, 1H), 6.59-6.57 (m, 1H) | 7.92 (s, 1H) |
8b(X = NH, R1 = ethynyl, Y = phenyl) |
CD3OD/400 MHz | 6.17 (d, J = 5.6 Hz, 1H) | 4.54-4.51 (m, 1H) | 4.24-4.21 (m, 1H) | 3.67-3.64 (m, 1H) | 3.89-3.83 (m, 1H), 3.75-3.70 (m, 1H) | 7.86-7.82 (m, 2H), 7.56-7.52 (m, 1H), 7.49-7.44 (m, 2H) | 8.08 (s, 1H) | 3.73 (s, 1H) | 7.79 (s, 1H) |
8c(X = NH, R1 = ethynyl, Y = p-methoxyphenyl) | CD3OD/400 MHz | 6.17 (d, J = 6.0 Hz, 1H) | 4.54-4.51 (m, 1H) | 4.23-4.21 (m, 1H) | 3.65-3.62 (m, 1H) | 3.87-3.81 (m, 1H), 3.73-3.70 (m, 1H) | 7.84-7.81 (m, 2H), 7.01-6.98 (m, 2H), 3.85 (s, 3H) | 8.09 (s, 1H) | 3.73 (s, 1H) | 7.78 (s, 1H) |
8d(X = NH, R1 = CN, Y = phenyl) |
CD3OD/400 MHz | 6.16 (d, J = 5.7 Hz, 1H) | 4.50-4.46 (m, 1H) | 4.27-4.19 (m, 1H) | 3.65-3.62 (m, 1H) | 3.88-3.82 (m, 1H), 3.74-3.68 (m, 1H) | 7.85-7.81 (m, 2H), 7.55-7.51 (m, 1H), 7.47-7.43 (m, 2H) | 8.10 (s, 1H) | __ | 7.80 (s, 1H) |
8e(X = NH, R1 = CONH2, Y = phenyl) |
CD3OD/400 MHz | 6.15 (d, J = 5.6 Hz, 1H) | 4.52-4.47 (m, 1H) | 4.25-4.18 (m, 1H) | 3.63-3.61 (m, 1H) | 3.89-3.85 (m, 1H), 3.75-3.66 (m, 1H) | 7.86-7.79 (m, 2H), 7.56-7.50 (m, 1H), 7.46-7.42 (m, 2H) | 8.09 (s, 1H) | __ | 7.78 (s, 1H) |
Compound | HRMS, m/z [M + H]+ | Molecular formula |
7a(X = O, R1 = 2-furanyl, Y = phenyl) | 453.1244 | C22H21N4O5S |
7b(X = O, R1 = ethynyl, Y = phenyl) | 411.1129 | C20H19N4O4S |
7c(X = O, R1 = ethynyl, Y = p-chlorophenyl) | 445.0737 | C20H18ClN4O4S |
7d(X = O, R1 = ethynyl, Y = p-methoxyphenyl) | 441.1231 | C21H21N4O5S |
7e(X = O, R1 = ethynyl, Y = 2,6-dimethylphenyl) | 439.1441 | C22H23N4O4S |
7f(X = O, R1 = ethynyl, Y = isonicotinyl) | 412.1082 | C19H18N5O4S |
7g(X = O, R1 = CN, Y = phenyl) | 412.1035 | C19H18N5O4S |
7h(X = O, R1 = CONH2, Y = phenyl) | 430.1140 | C19H20N5O5S |
8a(X = NH, R1 = 2-furanyl, Y = phenyl) | 452.1392 | C22H22N5O4S |
8b(X = NH, R1 = ethynyl, Y = phenyl) | 410.1277 | C20H20N5O3S |
8c(X = NH, R1 = ethynyl, Y = p-methoxyphenyl) | 440.1401 | C21H22N5O4S |
8d(X = NH, R1 = CN, Y = phenyl) | 411.1195 | C19H19N6O3S |
8e(X = NH, R1 = CONH2, Y = phenyl) | 429.1300 | C19H21N6O4S |
Compound |
NMR Solvent/Frequency | 1H NMR data (Chemical shift, δ ppm) | ||||||||
1' | 2' | 3' | 4' | 5' | Z group/=CH2 |
2 | 7 (R1 group) | 8 | ||
9a (R1 = ethynyl, Z = N3) (Compound III) |
DMSO-d 6/500 MHz | 6.10 (d, J = 6.8 Hz, 1H) | 4.52-4.48 (m, 1H) | 4.09-4.07 (m, 1H) | 3.38-3.34 (m, 1H) | 3.89-3.84 (m, 1H), 3.78-3.73 (m, 1H) | __ | 8.12 (s, 1H) | 4.30 (s, 1H) | 7.94 (s, 1H) |
9b(R1 = CN, Z = N3) (Compound III) | DMSO-d 6/500 MHz | 6.11 (d, J = 6.5 Hz, 1H) | 4.55-4.49 (m, 1H) | 4.11-4.08 (m, 1H) | 3.36-3.34 (m, 1H) | 3.87-3.85 (m, 1H), 3.79-3.72 (m, 1H) | __ | 8.15 (s, 1H) | __ | 7.96 (s, 1H) |
9c(R1 = CONH2, Z = N3) (Compound III) | DMSO-d 6/500 MHz | 6.09 (d, J = 6.6 Hz, 1H) | 4.54-4.47 (m, 1H) | 4.09-4.05 (m, 1H) | 3.35-3.33 (m, 1H) | 3.86-3.83 (m, 1H), 3.80-3.71 (m, 1H) | __ | 8.13 (s, 1H) | __ | 7.95 (s, 1H) |
10a(R1 = ethynyl, Z = NH2) (Compound III) | DMSO-d 6/400 MHz | 6.07 (d, J = 6.7 Hz, 1H) | 4.44-4.40 (m, 1H) | 4.14-4.11 (m, 1H) | 3.26-3.21 (m, 1H) | 3.03-2.97 (m, 1H), 2.85-2.78 (m, 1H) | 4.22 (t, 2H) | 8.12 (s, 1H) | 4.30 (s, 1H) | 7.94 (s, 1H) |
10b(R1 = CN, Z = NH2) (Compound III) | DMSO-d 6/400 MHz | 6.08 (d, J = 6.9 Hz, 1H) | 4.45-4.42 (m, 1H) | 4.16-4.13 (m, 1H) | 3.25-3.20 (m, 1H) | 3.05-2.96 (m, 1H), 2.84-2.75 (m, 1H) | 4.21 (t, 2H) | 8.14 (s, 1H) | __ | 7.95 (s, 1H) |
10c(R1 = CONH2, Z = NH2) (Compound III) | DMSO-d 6/400 MHz | 6.06 (d, J = 6.8 Hz, 1H) | 4.49-4.43 (m, 1H) | 4.15-4.12 (m, 1H) | 3.24-3.21 (m, 1H) | 3.07-2.95 (m, 1H), 2.86-2.77 (m, 1H) | 4.20 (t, 2H) | 8.13 (s, 1H) | __ | 7.94 (s, 1H) |
11ai(R1 = ethynyl, Z = NHCONH2) (Compound III) | CD3OD/400 MHz | 6.15 (d, J = 6.4 Hz, 1H) | 4.47-4.44 (m, 1H) | 4.15-4.12 (m, 1H) | 3.48-3.42 (m, 1H) | 3.06-3.00 (m, 2H) | __ | 8.09 (s, 1H) | 3.72 (s, 1H) | 7.77 (s, 1H) |
11aii(R1 = CN, Z = NHCONH2) (Compound III) | CD3OD/400 MHz | 6.16 (d, J = 6.2 Hz, 1H) | 4.46-4.42 (m, 1H) | 4.17-4.13 (m, 1H) | 3.46-3.41 (m, 1H) | 3.05-3.00 (m, 2H) | __ | 8.10 (s, 1H) | __ | 7.78 (s, 1H) |
11aiii(R1 = CONH2, Z = NHCONH2) (Compound III) | CD3OD/400 MHz | 6.15 (d, J = 6.3 Hz, 1H) | 4.45-4.41 (m, 1H) | 4.16-4.11 (m, 1H) | 3.45-3.40 (m, 1H) | 3.07-3.01 (m, 2H) | __ | 8.09 (s, 1H) | __ | 7.76 (s, 1H) |
11b (Z = NHCH2CH3) (Compound III) |
CD3OD/400 MHz | 6.10 (d, J = 5.2 Hz, 1H) | 4.42-4.40 (m, 1H) | 4.16-4.12 (m, 1H) | 3.50-3.46 (m, 1H) | 2.86-2.79 (m, 1H), 2.75-2.70 (m, 1H) | 2.59-2.50 (m, 2H), 1.11-1.09 (m, 3H) | 8.12 (s, 1H) | 3.73 (s, 1H) | 7.86 (s, 1H) |
12a (Z = morpholine) (Compound III) |
CD3OD/400 MHz | 6.09 (d, J = 4.4 Hz, 1H) | 4.33-4.30 (m, 1H) | 4.18-4.14 (m, 1H) | 3.64-3.58 (m, 1H) | 2.95-2.90 (m, 1H), 2.76-2.70 (m, 1H) | 3.72-3.68 (m, 4H), 2.62-2.52 (m, 4H) | 8.12 (s, 1H) | 3.74 (s, 1H) | 7.85 (s, 1H) |
12b (Compound IV) | CD3OD/400 MHz | 6.43 (d, J = 6.8 Hz, 1H) | 4.60-4.58 (m, 1H) | 4.46-4.42 (m, 1H) | __ | __ | 5.41 (merged dd, J 1 = J 2 = 0.8 Hz, 1H), 5.11 (s, 1H) | 8.13 (s, 1H) | 3.74 (s, 1H) | 7.67 (s, 1H) |
Compound | HRMS, m/z [M + H]+ | Molecular formula |
9a(R1 = ethynyl, Z = N3) (Compound III) | 332.0923 | C13H14N7O2S |
9b(R1 = CN, Z = N3) (Compound III) | 333.0837 | C12H13N8O2S |
9c(R1 = CONH2, Z = N3) (Compound III) | 351.0943 | C12H15N8O3S |
10a(R1 = ethynyl, Z = NH2) (Compound III) | 306.1031 | C13H16N5O2S |
10b(R1 = CN, Z = NH2) (Compound III) | 307.0932 | C12H15N6O2S |
10c(R1 = CONH2, Z = NH2) (Compound III) | 325.1038 | C12H17N6O3S |
11ai(R1 = ethynyl, Z = NHCONH2) (Compound III) | 349.1092 | C14H17N6O3S |
11aii(R1 = CN, Z = NHCONH2) (Compound III) | 350.0991 | C13H16N7O3S |
11aiii(R1 = CONH2, Z = NHCONH2) (Compound III) | 368.1096 | C13H18N7O4S |
11b (Z = NHCH2CH3) (Compound III) |
334.1299 | C15H20N5O2S |
12a (Z = morpholine) (Compound III) |
616.2805 | C30H42N5O7S |
12b (Compound IV) | 289.0759 | C13H13N4O2S |
Compound |
NMR Solvent/Frequency | 1H NMR data (Chemical shift, δ ppm) | ||||||
1' | 2' | 3' | 4' | 2 | 7 (R1 group) | 8 | ||
13a (R1 = ethynyl) |
CD3OD/400 MHz | 6.20 (d, J = 6.4 Hz, 1H) | 4.40-4.38 (m, 1H) | 4.43-4.41 (m, 1H) | 3.48-3.44 (m, 1H), 2.91-2.88 (m, 1H) | 8.10 (s, 1H) | 3.73 (s, 1H) | 7.76 (s, 1H) |
13b(R1 = 2-furanyl) | CD3OD/400 MHz | 6.29 (d, J = 6.7 Hz, 1H) | 4.43-4.40 (m, 1H) | 4.49-4.46 (m, 1H) | 3.47-3.46 (m, 1H), 2.93-2.90 (m, 1H) | 8.11 (s,1H) | 7.62-7.61 (m, 1H), 6.65-6.64 (m, 1H), 6.56-6.54 (m 1H) | 7.82 (s, 1H) |
13c(R1 = 2-thiofuranyl) | DMSO-d 6/500 MHz | 6.20 (d, J = 7.3 Hz, 1H) | 4.31-4.29 (m, 1H) | 4.55-4.50 (m, 1H) | 3.42-3.39 (m, 1H), 2.76-2.74 (m, 1H) | 8.15 (s, 1H) | 7.57-7.56 (m, 1H), 7.18-7.15 (m, 2H) | 7.67 (s, 1H) |
13d(R1 = phenyl) | CD3OD/500 MHz | 6.34 (d, J = 6.7 Hz, 1H) | 4.47-4.44 (m, 1H) | 4.53-4.51 (m, 1H) | 3.51-3.47 (m, 1H), 2.95-2.92 (m, 1H) | 8.16 (s, 1H) | 7.53-7.48 (m, 4H), 7.41-7.38 (m, 1H) | 7.54 (s, 1H) |
13e(R1 = vinyl) | CD3OD/400 MHz | 6.23 (d, J = 6.4 Hz, 1H) | 4.41-4.39 (m, 1H) | 4.44-4.42 (m, 1H) | 3.46-3.42 (m, 1H), 2.91-2.87 (m, 1H) | 8.15 (s, 1H) | 7.01-6.94 (m, 1H), 5.59-5.54 (m, 1H), 5.24-5.21 (m, 1H) | 7.59 (s, 1H) |
13f(R1 = CN) | CD3OD/400 MHz | 6.21 (d, J = 6.5 Hz, 1H) | 4.42-4.39 (m, 1H) | 4.44-4.43 (m, 1H) | 3.47-3.45 (m, 1H), 2.90-2.89 (m, 1H) | 8.12 (s, 1H) | __ | 7.77 (s, 1H) |
13g(R1 = CONH2) | CD3OD/400 MHz | 6.20 (d, J = 6.6 Hz, 1H) | 4.43-4.40 (m, 1H) | 4.46-4.44 (m, 1H) | 3.46-3.43 (m, 1H), 2.92-2.88 (m, 1H) | 8.11 (s, 1H) | __ | 7.77 (s, 1H) |
Compound | HRMS, m/z [M + H]+ | Molecular formula |
13a(R1 = ethynyl) | 277.0756 | C12H13N4O2S |
13b(R1 = 2-furanyl) | 319.0868 | C14H15N4O3S |
13c(R1 = 2-thienyl) | 335.0639 | C14H15N4O2S2 |
13d(R1 = phenyl) | 329.1075 | C16H17N4O2S |
13e(R1 = vinyl) | 279.0906 | C12H15N4O2S |
13f(R1 = CN) | 278.0667 | C11H12N5O2S |
13g(R1 = CONH2) | 296.0773 | C11H14N5O3S |
Compound | NTRK1 | CSNK1D | DYRK1A | DYRK1B | FLT3 |
1a | +++ | ++ | +++ | +++ | ND |
1b | +++ | +++ | ++ | ++ | ND |
2a | +++ | ++ | ++ | ++ | ND |
2b | ++ | +++ | ++ | ++ | ND |
2c | - | - | - | - | ND |
2d | - | + | - | - | ND |
3 | ++ | ++ | +++ | +++ | ND |
4a | ++ | + | + | + | ND |
4b | + | + | + | + | ND |
4c | + | + | - | - | ND |
4d | ++ | + | - | - | ND |
5 | ++ | ++ | +++ | ++ | ND |
6 | + | ++ | +++ | ++ | ND |
7a | +++ | ++ | +++ | +++ | ND |
7b | +++ | ++ | ++ | ++ | ND |
7c | ++ | ++ | ++ | ++ | ND |
7d | ++ | ++ | ++ | ++ | ND |
7e | +++ | ++ | ++ | ++ | ND |
7f | +++ | ++ | ++ | ++ | ND |
7g | ++ | +++ | +++ | +++ | ND |
7h | ++ | +++ | +++ | +++ | ND |
8a | +++ | ++ | +++ | +++ | ND |
8b | +++ | ++ | +++ | +++ | ++ |
8c | +++ | ++ | +++ | ++ | ND |
8d | +++ | ++ | ++ | +++ | ND |
8e | ++ | ++ | ++ | ++ | ND |
9a | +++ | +++ | +++ | +++ | +++ |
9b | +++ | +++ | +++ | +++ | ND |
9c | +++ | +++ | +++ | +++ | ND |
10a | +++ | +++ | +++ | ++ | +++ |
10b | ++ | ++ | +++ | +++ | ND |
10c | ++ | ++ | ++ | ++ | ND |
11ai | +++ | +++ | +++ | ++ | +++ |
11aii | ++ | ++ | ++ | ++ | ND |
11aiii | ++ | ++ | ++ | ++ | ND |
11b | +++ | +++ | ++ | ++ | ND |
12a | ++ | ++ | +++ | ++ | ND |
12b | +++ | +++ | +++ | +++ | ND |
13a | ++ | ++ | ++ | ++ | ND |
13b | ++ | ++ | +++ | +++ | ND |
13c | +++ | +++ | ++ | ++ | ND |
13d | ++ | ++ | ++ | ++ | ND |
13e | ++ | ++ | ++ | ++ | ND |
13f | ++ | ++ | ++ | +++ | ND |
13g | +++ | +++ | ++ | +++ | ND |
14 | ++ | ++ | +++ | +++ | ND |
Compound | IC50 (μM) | |||||
A549 | HCT116 | MDA-MB-231 | SK-HEP-1 | SNU638 | PC-3 | |
1a | 1.02 | 2.16 | 3.31 | 3.38 | 1.95 | 2.46 |
1b | 1.65 | 1.74 | 2.72 | 1.38 | 2.41 | 2.48 |
2a | 0.97 | 0.56 | 0.31 | 0.22 | 0.47 | 0.20 |
2b | 7.57 | 6.35 | 8.83 | 7.81 | 6.32 | 9.21 |
2c | > 50 | > 50 | > 50 | > 50 | > 50 | > 50 |
2d | 41.62 | 30.57 | 30.16 | 10.34 | 27.47 | 15.43 |
3 | 0.06 | 0.03 | 0.05 | 0.05 | 0.03 | 0.004 |
4a | > 50 | > 50 | 45.51 | 6.05 | > 50 | > 50 |
4b | > 50 | > 50 | > 50 | > 50 | > 50 | > 50 |
4c | > 50 | > 50 | 29.57 | > 50 | > 50 | > 50 |
4d | > 50 | > 50 | 30.63 | 8.31 | > 50 | > 50 |
5 | 2.58 | 1.59 | 2.24 | 1.79 | 1.22 | 2.18 |
6 | 1.99 | 1.35 | 2.10 | 1.66 | 1.13 | 1.80 |
7a | 6.05 | 2.21 | 8.24 | 1.07 | 3.54 | > 50 |
7b | 3.19 | 2.86 | 2.13 | 0.57 | 1.31 | 2.05 |
7c | 0.27 | 0.23 | 0.29 | 0.18 | 0.13 | 0.23 |
7d | 0.35 | 0.30 | 0.36 | 0.25 | 0.19 | 0.33 |
7e | 6.47 | 6.42 | 4.68 | 4.39 | 4.84 | 5.59 |
7f | 0.070 | 0.038 | 0.074 | 0.050 | 0.048 | 0.078 |
7g | 2.58 | 3.60 | 1.56 | 5.62 | 3.78 | 2.96 |
7h | 4.78 | 1.61 | 6.79 | 5.09 | 5.23 | 3.56 |
8a | >50 | >50 | >50 | 1.15 | >50 | >50 |
8b | 28.56 | 26.31 | 32.39 | 21.25 | 23.34 | 29.12 |
8c | 10.07 | 13.72 | 10.36 | 12.21 | 12.22 | 14.75 |
8d | 11.16 | 8.90 | 9.34 | 13.83 | 23.70 | 6.67 |
8e | 45.16 | 12.45 | 6.78 | 10.01 | 9.34 | 4.65 |
9a | 0.17 | 0.37 | 0.42 | 0.26 | 0.33 | ND |
9b | 0.23 | 0.56 | 0.38 | 1.05 | 0.12 | 0.45 |
9c | 0.24 | 0.86 | 0.26 | 0.78 | 0.35 | 0.36 |
10a | 1.58 | 1.35 | 1.87 | 1.40 | 1.33 | 1.98 |
10b | 3.83 | 2.78 | 4.75 | 1.63 | 1.47 | 2.45 |
10c | 2.51 | 1.37 | 2.43 | 1.76 | 2.56 | 2.74 |
11ai | 4.59 | 2.77 | 4.11 | 3.31 | 2.45 | 3.54 |
11aii | 2.45 | 1.83 | 1.08 | 2.87 | 6.73 | 3.56 |
11aiii | 4.53 | 1.36 | 2.46 | 7.34 | 5.57 | 2.81 |
11b | 12.25 | 12.84 | 14.52 | 13.01 | 10.78 | 14.01 |
12a | 11.71 | 9.72 | 11.23 | 10.24 | 9.70 | 13.20 |
12b | 0.25 | 0.73 | 0.50 | 0.31 | 0.62 | ND |
13a | 0.59 | 0.85 | 1.15 | 1.27 | 1.20 | 1.39 |
13b | 0.96 | 0.86 | 1.32 | 0.64 | 1.31 | 1.74 |
13c | 2.91 | 3.38 | 5.16 | 2.74 | 4.12 | 7.01 |
13d | 6.83 | 4.31 | 5.93 | 7.81 | 5.66 | 9.90 |
13e | 4.33 | 2.84 | 5.33 | 5.11 | 3.54 | 5.34 |
13f | 2.36 | 6.37 | 2.41 | 5.78 | 9.35 | 2.45 |
13g | 5.27 | 9.73 | 5.67 | 2.13 | 8.46 | 2.24 |
14 | 0.35 | 7.28 | 0.52 | 1.37 | 5.46 | 2.45 |
Claims (8)
- 하기 화학식 1로 표현되는 뉴클레오사이드 유도체 또는 이의 약학적으로 허용가능한 염.<화학식 1>(상기 화학식 1에서,X는 산소(O) 또는 황(S)이고,R은 수소(H); 치환 또는 비치환된 C1 내지 C10의 알킬(alkyl); 또는 치환 또는 비치환된 C6 내지 C20의 아릴(aryl) 또는 알킬아릴(alkylaryl)이고,R1은 치환 또는 비치환된 C2 내지 C10의 헤테로아릴(heteroaryl); 치환 또는 비치환된 C2 내지 C8의 알케닐(alkenyl); 치환 또는 비치환된 C6 내지 C20의 아릴(aryl); 치환 또는 비치환된 C2 내지 C8의 알키닐(alkynyl); 시아노(cyano); 아미드(amide); 또는 카복실(carboxyl)이고,R2는 할로겐(halogen); 치환 또는 비치환된 아민(amine); 또는 치환 또는 비치환된 C6 내지 C20의 아릴(aryl) 또는 알킬아릴(alkylaryl)이고,Y는 수소(H); 히드록시(hydroxy), 에스테르(ester), 알콕시(alkoxy), 아릴(aryl), 헤테로아릴(heteroaryl), 헤테로사이클로알킬(heterocycloalkyl), 사이클로알킬(cycloalkyl), 아자이드 (azide), 아민(amine), 치환된 아민, 유레아(urea), 또는 아미드(amide)로 치환된 알킬(alkyl); 또는 =CZ2이며, 상기 Z는 각각 독립적으로 수소(H) 또는 C2 내지 C8의 알킬(alkyl)이다.
- 제1 항에 있어서,상기 헤테로아릴은 퓨라닐(furanyl), 싸이오페닐(thiophenyl), 피롤릴(pyrrolyl), 피라닐(pyranyl), 피라졸릴(pyrazolyl), 피리디닐(pyridinyl), 트리아졸릴(triazolyl), 이미다졸릴(imidazolyl), 싸이아졸릴(thiazolyl), 피리미디닐(pyrimidinyl), 피라지닐(pyrazinyl), 피리다지닐(pyridazinyl), 인돌릴(indolyl), 퀴놀리닐(quinolinyl) 또는 퓨리닐(purinyl)이고,상기 헤테로사이클로알킬은 테트라하이드로퓨라닐(tetrahydrofuranyl), 싸이올레닐(thiolanyl), 피롤리디닐(pyrrolidinyl), 테트라하이드로피라닐(tetrahydropyranyl), 피페리디닐(piperidinyl), 다이옥사닐(dioxanyl), 몰폴리노(morpholino) 또는 테트라하이드로피리미디닐(tetrahydropyrimidinyl)이고,상기 아릴은 페닐(phenyl), 나프탈레닐(naphthalenyl), 안트라세닐(anthracenyl) 또는 페난트레닐(phenanthrenyl)일 수 있고, 상기 알킬아릴은 벤질(benzyl)이고,상기 알키닐은 에티닐(ethynyl), 프로피닐(propynyl), 부티닐(butynyl), 펜티닐(pentynyl), 헥시닐(hexynyl), 헵티닐(heptynyl), 옥티닐(octynyl), 노니닐(nonynyl) 또는 데시닐(decynyl)이고,상기 알케닐은 에테닐(ethenyl), 프로페닐(propenyl), 부테닐(butenyl), 펜테닐(pentenyl), 헥세닐(hexenyl), 헵테닐(heptenyl), 옥테닐(octenyl), 노네닐(nonenyl) 또는 데세닐(decenyl)이고,상기 알킬은 메틸(methyl), 에틸(ethyl), 프로필(propyl), 부틸(butyl) 또는 펜틸(pentyl)인뉴클레오사이드 유도체 또는 이의 약학적으로 허용가능한 염.
- 제1 항에 있어서,R1은 퓨라닐(furanyl), 싸이오페닐(thiophenyl), 바이닐(vinyl), 페닐(phenyl), 싸이오몰폴리노(Thiomorpholino)페닐, 싸이오몰폴리노다이옥사이드페닐, 설폰아마이드(sulfonamide)페닐, 에틸설폰아마이드페닐, 에티닐(ethynyl), 프로피닐(propynyl), 뷰티닐(butynyl), 디메틸뷰티닐(dimethylbutynyl), 사이클로프로필에티닐(cyclopropylethynyl), 시아노(cyano), 아미드(amide) 또는 카복시(carboxy)인R2는 염소(Cl) 또는 아민(-NH2)일 수 있고,뉴클레오사이드 유도체 또는 이의 약학적으로 허용가능한 염.
- 제1 항에 있어서,Y는 수소, -CH2OH, -CH2OCOAr, -CH2N3, -CH2NH2, -CH2NHCOAr, -CH2NHCONH2, -CH2N-alkyl, -CH2N-cycloalkyl, -CH2N(CH2CH2)2O 또는 =CH2이되,상기 'Ar'은 페닐, 클로로(chloro)페닐, 메톡시(methoxy)페닐, 디메틸(dimethyl)페닐 또는 니코티닐(nicotinyl)이고, 상기 'alkyl'은 메틸, 에틸, 프로필, 부틸 또는 펜틸이고, 상기 'cycloalkyl'은 사이클로프로필(cyclopropyl), 사이클로뷰틸(cyclobutyl), 사이클로펜틸(cyclopentyl) 또는 사이클로헥실(cyclohexyl)인뉴클레오사이드 유도체 또는 이의 약학적으로 허용가능한 염.
- 제1 항 내지 제5 항 중 어느 한 항의 뉴클레오사이드 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는암의 예방 또는 치료용 약학적 조성물.
- 제6 항에 있어서,상기 암은 폐암, 결장암, 유방암, 간암, 위암 및 전립선암으로 이루어진 군에서 선택되는 하나 이상인암의 예방 또는 치료용 약학적 조성물.
- 제6 항에 있어서,상기 뉴클레오사이드 유도체 또는 이의 약학적으로 허용가능한 염은 인산화효소 저해 활성을 갖는암의 예방 또는 치료용 약학적 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022287865A AU2022287865A1 (en) | 2021-06-08 | 2022-05-31 | Nucleoside derivative having multi-target kinase inhibitory activity and pharmaceutical composition for preventing and treating cancer comprising same |
CN202280041325.7A CN117460736A (zh) | 2021-06-08 | 2022-05-31 | 具有多靶标磷酸化酶抑制活性的核苷衍生物及包含其的癌症的预防和治疗用药学组合物 |
CA3220826A CA3220826A1 (en) | 2021-06-08 | 2022-05-31 | Nucleoside derivative having multi-target kinase inhibitory activity and pharmaceutical composition for preventing and treating cancer comprising same |
EP22820464.0A EP4353733A2 (en) | 2021-06-08 | 2022-05-31 | Nucleoside derivative having multi-target kinase inhibitory activity and pharmaceutical composition for preventing and treating cancer comprising same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0073914 | 2021-06-08 | ||
KR1020210073914A KR102639275B1 (ko) | 2021-06-08 | 2021-06-08 | 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022260336A2 true WO2022260336A2 (ko) | 2022-12-15 |
WO2022260336A3 WO2022260336A3 (ko) | 2023-02-02 |
Family
ID=84426168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/007747 WO2022260336A2 (ko) | 2021-06-08 | 2022-05-31 | 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4353733A2 (ko) |
KR (2) | KR102639275B1 (ko) |
CN (1) | CN117460736A (ko) |
AU (1) | AU2022287865A1 (ko) |
CA (1) | CA3220826A1 (ko) |
WO (1) | WO2022260336A2 (ko) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140851A (en) * | 1977-11-21 | 1979-02-20 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides |
US5674998A (en) * | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
EP1212326A4 (en) * | 1999-08-27 | 2003-08-20 | Icn Pharmaceuticals | NUCLEOSIDE ANALOGS OF PYRROLO 2,3-d] PYRIMIDINE |
TWI718526B (zh) * | 2018-12-13 | 2021-02-11 | 中央研究院 | 經調節泛蛋白化之癌症治療及/或預防 |
-
2021
- 2021-06-08 KR KR1020210073914A patent/KR102639275B1/ko active Application Filing
-
2022
- 2022-05-31 CN CN202280041325.7A patent/CN117460736A/zh active Pending
- 2022-05-31 EP EP22820464.0A patent/EP4353733A2/en active Pending
- 2022-05-31 AU AU2022287865A patent/AU2022287865A1/en active Pending
- 2022-05-31 CA CA3220826A patent/CA3220826A1/en active Pending
- 2022-05-31 WO PCT/KR2022/007747 patent/WO2022260336A2/ko active Application Filing
-
2024
- 2024-02-14 KR KR1020240021345A patent/KR20240023587A/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR20240023587A (ko) | 2024-02-22 |
KR102639275B1 (ko) | 2024-02-21 |
WO2022260336A3 (ko) | 2023-02-02 |
AU2022287865A1 (en) | 2024-01-04 |
CN117460736A (zh) | 2024-01-26 |
EP4353733A2 (en) | 2024-04-17 |
KR20220165373A (ko) | 2022-12-15 |
CA3220826A1 (en) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021112538A1 (en) | Glp-1 receptor agonist | |
WO2021040356A1 (en) | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition | |
AU2018353759B2 (en) | Heterocyclic compound as a protein kinase inhibitor | |
EA026557B1 (ru) | Промежуточные соединения для получения модуляторов толл-подобных рецепторов | |
WO2020149723A1 (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020149553A1 (ko) | 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 | |
WO2023282702A1 (ko) | Shp2 억제제 및 이의 용도 | |
WO2022131741A1 (ko) | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 | |
WO2022177302A1 (ko) | Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도 | |
WO2022260336A2 (ko) | 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 | |
WO2021261970A1 (ko) | 신규한 화합물 및 이를 포함하는 내성암 예방 또는 치료용 약학 조성물 | |
WO2023017442A1 (en) | Novel plk1 degradation inducing compound | |
WO2020185044A1 (ko) | 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물 | |
AU2021327622B2 (en) | Novel compounds having inhibitory activity on prostaglandin E2 receptor and uses thereof | |
WO2020263058A1 (ko) | 아미노시아노피리딘 유도체 및 그의 용도 | |
KR20240018139A (ko) | 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 | |
WO2019004693A1 (ko) | 알콕시알렌 화합물로부터 금속 촉매를 사용하여 n-글리코사이드 화합물을 위치선택적 및 입체선택적으로 제조하는 방법 | |
AU2019344240A1 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
WO2022225238A1 (ko) | 헤테로아릴 유도체 화합물 및 이의 용도 | |
WO2021261969A1 (ko) | 신규한 화합물의 제조방법 | |
WO2019039905A1 (ko) | 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물 | |
WO2020106059A1 (ko) | Irak4 저해제로서 신규의 삼중고리 화합물 | |
WO2024014885A1 (ko) | 신규 바이사이클릭 헤테로아릴 화합물 및 이의 용도 | |
WO2023158221A1 (ko) | 프로스타글란딘 e2 수용체에 대한 저해 활성을 갖는 신규 화합물 및 항암제를 포함하는 암 치료용 약학 조성물 | |
WO2023022497A1 (ko) | Sos1 억제제 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22820464 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3220826 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2023575577 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18568288 Country of ref document: US Ref document number: 202280041325.7 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022287865 Country of ref document: AU Ref document number: AU2022287865 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022287865 Country of ref document: AU Date of ref document: 20220531 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022820464 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022820464 Country of ref document: EP Effective date: 20240108 |